Due to a rate of sodium levothyroxine slightly lower than the specifications, several tablets prescribed against hyperthyroidism have been the subject of a recall.
- The ANSM recently announced a massive reminder of several levothyroxine boxes produced by the Sanofi laboratory.
- The latter follows the demonstration of a sodium levothyroxine level slightly lower than the specifications.
- Patients with these drugs must stop taking the tablets and reporting them in pharmacies in order to exchange.
Located at the front of the neck, the thyroid is an endocrine gland. Clearly, this organ produces hormones, namely substances transported in the blood and which diffuse in all parts of the body. These thyroid hormones act as messengers capable of ordering actions remotely from the thyroid. When produced at high rates by the gland, we speak of hyperthyroidism. This is manifested by weight loss, thermophobia, heart palpitations, insomnia, a drop in muscle strength, fatigue, tremors or nausea.
In order to combat this disorder, drugs, called “synthetic antithyroidian”, are prescribed to reduce the production of thyroid hormones. After Health insurancethey make it possible to obtain normal values in 3 to 8 weeks. “Maintenance treatment must then be continued for several months (12 to 18 months).”
Levothyroxine boxes recalled due to rate lower than specifications
January 23, The National Medicines Safety Agency (ANSM) pointed out that several boxes of Lévothyroxine, produced by the Sanofi laboratory, were removed from the sale by precautionary measure. The reason? A rate of sodium levothyroxine slightly lower than the specifications highlighted by the pharmaceutical group during a stability study. “No case of pharmacovigilance in relation to this defect has been reported on the prizes to date”, Indicates the firm.
The drugs concerned by this recall are called:
- L -Thyroxin Henning 50 micrograms, Sarbed tablet – CIP: 34009 301 197 7 8, more specifically the lots: “3R11V – Epremption: 05/2025” and “3R1PJ – EXPUTION: 06/2025”
- L -Thyroxin Henning 75 micrograms, scored tablet – CIP: 34009 301 197, more specifically the lots: “3R14C – Extending: 05/2025” and “3R879 – EXPUTION: 04/2025”
Hyperthyroidism: “Contact, by all the means they have” patients taking this drug
ANSM asks pharmacists to “Contact, by all the means they have”, People who have received a box (s) of the lots concerned. As for patients with a box of lots affected by the recall, they should no longer take these tablets and must bring in the pharmacy box (s) to proceed to an exchange. Because no, patients should not stop taking their treatment against hyperthyroidism.
